{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:34:45Z","timestamp":1791178485988,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.exphem.2013.01.008","type":"journal-article","created":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T17:48:49Z","timestamp":1359740929000},"page":"424-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"41","author":[{"given":"Giorgio","family":"La Nasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Littera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Langiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Orr\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Orr\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carcassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2013.01.008_bib1","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/cbt.8.23.10455","article-title":"Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR)","volume":"8","author":"Purdy","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.exphem.2013.01.008_bib2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.leu.2404641","article-title":"Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy","volume":"21","author":"Simula","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.01.008_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"European Leukemia Net. Response definitions and European Leukemianet Management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2013.01.008_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2013.01.008_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.beha.2009.08.001","article-title":"Treatment strategies for CML","volume":"22","author":"Goldman","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2013.01.008_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ni0508-477","article-title":"Natural killer cell recognition of missing self","volume":"9","author":"K\u00e4rre","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.exphem.2013.01.008_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.genom.7.080505.115726","article-title":"The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense","volume":"7","author":"Bashirova","year":"2006","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.exphem.2013.01.008_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1600-065X.2002.19004.x","article-title":"The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism","volume":"190","author":"Hsu","year":"2002","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2013.01.008_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1479-5876-4-44","article-title":"Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population","volume":"4","author":"Bontadini","year":"2006","journal-title":"J Transl Med"},{"key":"10.1016\/j.exphem.2013.01.008_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2009.03208.x","article-title":"The extensive polymorphism of KIR genes","volume":"129","author":"Middleton","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.exphem.2013.01.008_bib11","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.4049\/jimmunol.180.6.3969","article-title":"Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3","volume":"180","author":"Moesta","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2013.01.008_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4049\/jimmunol.178.1.235","article-title":"Functional polymorphism of the KIR3DL1\/S1 receptor on human NK cells","volume":"178","author":"O'Connor","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2013.01.008_bib13","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/sj.leu.2403525","article-title":"Identification of natural killer cell receptor phenotypes associated with leukemia","volume":"18","author":"Verheyden","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.01.008_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1399-0039.2009.01235.x","article-title":"Killer immunoglobulin-like receptors (KIR2DL2 and\/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukemia","volume":"73","author":"Middleton","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.exphem.2013.01.008_bib15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","article-title":"KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib","volume":"26","author":"Marin","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.01.008_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","article-title":"Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia","volume":"40","author":"Kreutzman","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2013.01.008_bib17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2012-04-421016","article-title":"Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia","volume":"120","author":"Ali","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.01.008_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0198-8859(02)00373-7","article-title":"Relevance of KIR gene polymorphisms in bone marrow transplantation outcome","volume":"63","author":"Gagne","year":"2002","journal-title":"Human Immunol"},{"key":"10.1016\/j.exphem.2013.01.008_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00251-002-0497-x","article-title":"Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression","volume":"54","author":"Yawata","year":"2002","journal-title":"Immunogenetics"},{"key":"10.1016\/j.exphem.2013.01.008_bib20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s12032-011-9932-x","article-title":"Killer cell immunoglobulin-like receptor genes in patients with breast cancer","volume":"29","author":"Ozturk","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.exphem.2013.01.008_bib21","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.humimm.2010.06.019","article-title":"Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors","volume":"71","author":"Al Omar","year":"2010","journal-title":"Human Immunol"},{"key":"10.1016\/j.exphem.2013.01.008_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2567.2011.03415.x","article-title":"Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer","volume":"133","author":"Al Omar","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.exphem.2013.01.008_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00262-004-0575-z","article-title":"Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals","volume":"54","author":"Naumova","year":"2005","journal-title":"Cancer Immunology Immunother"},{"key":"10.1016\/j.exphem.2013.01.008_bib24","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1158\/0008-5472.CAN-10-4179","article-title":"Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma","volume":"71","author":"Platonova","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2013.01.008_bib25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.23239","article-title":"Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells","volume":"112","author":"Carrega","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2013.01.008_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2407-9-186","article-title":"Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions","volume":"9","author":"Garcia-Iglesias","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2013.01.008_bib27","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumorimmunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2013.01.008_bib28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000339498","article-title":"Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127(low) regulatory T cells","volume":"128","author":"Fozza","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.exphem.2013.01.008_bib29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2010-08-264085","article-title":"Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation","volume":"117","author":"Moretta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.01.008_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2141.2011.08923.x","article-title":"Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm","volume":"156","author":"Littera","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2013.01.008_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2013.01.008_bib32","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/eji.200939728","article-title":"Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity","volume":"39","author":"Ghio","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.exphem.2013.01.008_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/430351","article-title":"Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection","volume":"192","author":"L\u00f3pez-V\u00e1zquez","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.exphem.2013.01.008_bib34","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.25233","article-title":"The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity","volume":"127","author":"Salih","year":"2010","journal-title":"Int J\u00a0Cancer"},{"key":"10.1016\/j.exphem.2013.01.008_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/icb.2012.60","article-title":"Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?","volume":"91","author":"Burr","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.exphem.2013.01.008_bib36","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-Cadherin and Wnt-\u03b2-catenin signaling","author":"Zhang","year":"2013","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X13000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X13000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:49Z","timestamp":1759566649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X13000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0301472X13000118"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2013.01.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2013.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}